Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

1. Age \>/= 3 years to \</= 21 years. 2. Histologically or genetically proven unilateral primary or metastatic active pleural malignancy. 3. Radiologic workup must demonstrate that the thoracic disease is confined to only one hemi-thoracic cavity and must be deemed potentially resectable by the surgical team. 4. The extrathoracic disease must be controlled. 5. Patients must have a minimum expected duration of survival of 8 weeks as determined and documented by the attending surgeon or medical oncologist. 6. Patients must not have any systemic illness which precludes them from being an operative candidate. 7. Patients must have Adequate Renal Function Defined as: Creatinine clearance or radioisotope GFR \>/=70ml/min/1.73 m\^2 or a serum creatinine based on age/gender less than listed value in the table below: 1 to \< 2 years 0.6 mg/dL for both males and females, 2 to \< 6 years 0.8 mg/dL for both males and females, 6 to \< 10 years 1 mg/dL for both males and females, 10 to \< 13 years 1.2 mg/dL for both males and females, 13 to \< 16 years 1.5 mg/dL for males and 1.4 mg/dL for females, \>/= 16 years 1.7 for males and 1.4 for females 8. Patients will be eligible if the WBC is \>/=1500/µl or ANC is \>/=1,000 and platelets are \>/= 50,000/mm\^3 9. Adequate Liver Function Defined as: -Bilirubin (sum of conjugated + unconjugated) \</= 1.5 x upper limit of normal (ULN) for age -SGPT (ALT) \</=110 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L. -Serum albumin \>/= 2 g/dL. 10. Patients must be recovered from any toxicity from all prior chemotherapy, immunotherapy, or radiotherapy and be at least 14 days past the date of their last treatment

1. Patients will be ineligible if they have any concomitant cardiopulmonary disease which would place them at unacceptable risk for a major surgical procedure 2. Patients who have failed previous hemi-thoracic platinum therapy will be ineligible ("Failed" is having disease recurrence \</= 3 months). 3. No pregnant or lactating females. 4. Patients will be ineligible if they have a lymphoma diagnosis.